Showing results (101-110 of 245) with videos related to
Sort By:
Pageof 25
Journal of Clinical Medicine|February 22, 2020
Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid LeukemiaCiera L Patzke, Alison P Duffy, Vu H Duong, et al.Frontiers in Oncology|January 10, 2022
Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic TargetNoa G Holtzman, Michael S Lebowitz, Rima Koka, et al.Leukemia & Lymphoma|July 17, 2012
Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experienceDan P Zandberg, Franklin Hendrick, Emily Vannorsdall, et al.Investigational New Drugs|February 28, 2013
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndromeIvana Gojo, Alexander Perl, Selina Luger, et al.Cancer|July 1, 2011
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemiaJorge Cortes, Hagop Kantarjian, Edward D Ball, et al.Cancer Chemotherapy and Pharmacology|July 13, 2005
Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemiaHans Minderman, Kieran L O'Loughlin, Patrick F Smith, et al.Journal of Hematopathology|October 9, 2018
High-Risk Acute Promyelocytic Leukemia with Unusual T/Myeloid Immunophenotype Successfully Treated with ATRA and Arsenic Trioxide-Based RegimenZeba N Singh, Vu H Duong, Rima Koka, et al.Biorxiv : the Preprint Server for Biology|December 4, 2025
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitorsAditi Chatterjee, Moaath K Mustafa Ali, Christopher M Bailey, et al.Leukemia|June 2, 2026
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitorsAditi Chatterjee, Moaath K Mustafa Ali, Christopher M Bailey, et al.Investigational New Drugs|October 31, 2006
The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cellsTracy A Brooks, Kieran L O'Loughlin, Hans Minderman, et al.Pageof 25